CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors

Christopher Moertel, Francisco Martinez-Puerta, Grace G.Elizabeth Pluhar, Maria Graciela Castro, Michael Olin

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
JournalExpert Opinion on Investigational Drugs
DOIs
StateAccepted/In press - 2022

Bibliographical note

Funding Information:
No funding was received for this work.

Keywords

  • CD200
  • Immune checkpoint
  • glioblastoma
  • immunotherapy

Cite this